The margin for error in the US homeopathic industry could spread rather than shrink with the Food and Drug Administration withdrawing a policy guide that for three decades allowed sales of the products before it finalizes a guidance on compliance with agency regulations.
In the revised draft guidance it published the same day it withdrew Compliance Policy Guide 400
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?